Cardiovascular disease (CVD) is the leading cause of death in the world. Risk assessment is crucial to identify high-risk individuals who require immediate attention as well as to guide the type and intensity of medical therapy to improve its prognosis. In the past decade, many risk prediction models have been proposed to estimate the risk of developing CVD. However, in patients with a history of CVD, the current models that are based on traditional risk factors provide limited power in predicting recurrent CV events. Precision medicine is based on an increased understanding of the molecular mechanism of diseases, so we are now better able to group patients who would best benefit from a specific treatment. Several biomarkers related with different pathophysiological pathways have been identified to predict cardiovascular events, and the incorporation of biomarkers into risk assessment may contribute to enhance risk stratification in secondary prevention.
The current Research Topic will include biomarkers related to genomics, lifestyle, and other newer areas of interest (e.g., digital biomarkers and therapeutics), as well as traditional biomarkers. Traditional CV biomarkers can cover multiple pathophysiologic pathways related with platelet, coagulation, fibrinolysis, inflammation, glucose, cholesterol, and B-type natriuretic peptide, and discusses the potential utility of these biomarkers in prediction and treatment of CV risk among patients with CVD.
Further research including original papers, reviews, and meta-analyses are needed to assess the validity of biomarkers and whether the strategy for incorporating biomarkers into clinical practice may help to optimize decision-making and therapeutic management. This series will be open for any issues related to this topic.
Conflicts of interest
YH Jeong has received honoraria for lectures from AstraZeneca, Daiichi Sankyo, Sanofi-Aventis,
Han-mi Pharmaceuticals, and Yuhan Pharmaceuticals; and research grants or support from Yuhan
Pharmaceuticals, Han-mi Pharmaceuticals, Sam-jin Pharmaceuticals, Biotronik, and U&I
Corporation. Paul.A.Gurbel. has received consulting fees and/or honoraria from Bayer, Hikari Dx, Janssen, Medicure, Otitopic, UpToDate and US WorldMeds, and institutional research grants from Amgen, Bayer, Haemonetics, Idorsia, Instrumentation Laboratories, Janssen, the NIH, Medicure, Otitopic and US
WorldMeds.
Cardiovascular disease (CVD) is the leading cause of death in the world. Risk assessment is crucial to identify high-risk individuals who require immediate attention as well as to guide the type and intensity of medical therapy to improve its prognosis. In the past decade, many risk prediction models have been proposed to estimate the risk of developing CVD. However, in patients with a history of CVD, the current models that are based on traditional risk factors provide limited power in predicting recurrent CV events. Precision medicine is based on an increased understanding of the molecular mechanism of diseases, so we are now better able to group patients who would best benefit from a specific treatment. Several biomarkers related with different pathophysiological pathways have been identified to predict cardiovascular events, and the incorporation of biomarkers into risk assessment may contribute to enhance risk stratification in secondary prevention.
The current Research Topic will include biomarkers related to genomics, lifestyle, and other newer areas of interest (e.g., digital biomarkers and therapeutics), as well as traditional biomarkers. Traditional CV biomarkers can cover multiple pathophysiologic pathways related with platelet, coagulation, fibrinolysis, inflammation, glucose, cholesterol, and B-type natriuretic peptide, and discusses the potential utility of these biomarkers in prediction and treatment of CV risk among patients with CVD.
Further research including original papers, reviews, and meta-analyses are needed to assess the validity of biomarkers and whether the strategy for incorporating biomarkers into clinical practice may help to optimize decision-making and therapeutic management. This series will be open for any issues related to this topic.
Conflicts of interest
YH Jeong has received honoraria for lectures from AstraZeneca, Daiichi Sankyo, Sanofi-Aventis,
Han-mi Pharmaceuticals, and Yuhan Pharmaceuticals; and research grants or support from Yuhan
Pharmaceuticals, Han-mi Pharmaceuticals, Sam-jin Pharmaceuticals, Biotronik, and U&I
Corporation. Paul.A.Gurbel. has received consulting fees and/or honoraria from Bayer, Hikari Dx, Janssen, Medicure, Otitopic, UpToDate and US WorldMeds, and institutional research grants from Amgen, Bayer, Haemonetics, Idorsia, Instrumentation Laboratories, Janssen, the NIH, Medicure, Otitopic and US
WorldMeds.
